.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Fish and Richardson
Boehringer Ingelheim
Federal Trade Commission
US Army
Argus Health
Express Scripts
Colorcon
AstraZeneca
Cerilliant

Generated: December 15, 2017

DrugPatentWatch Database Preview

Cppi Cv Company Profile

« Back to Dashboard

What is the competitive landscape for CPPI CV, and what generic alternatives to CPPI CV drugs are available?

CPPI CV has one approved drug.

There are three US patents protecting CPPI CV drugs.

There are sixty-eight patent family members on CPPI CV drugs in thirty-nine countries and twenty-one supplementary protection certificates in ten countries.

Summary for Cppi Cv

International Patents:68
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Cppi CvSUTENTsunitinib malateCAPSULE;ORAL021938-003Jan 26, 2006RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Cppi CvSUTENTsunitinib malateCAPSULE;ORAL021938-004Mar 31, 2009RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Cppi CvSUTENTsunitinib malateCAPSULE;ORAL021938-001Jan 26, 2006RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Cppi CvSUTENTsunitinib malateCAPSULE;ORAL021938-003Jan 26, 2006RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Cppi CvSUTENTsunitinib malateCAPSULE;ORAL021938-004Mar 31, 2009RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Cppi CvSUTENTsunitinib malateCAPSULE;ORAL021938-001Jan 26, 2006RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Cppi CvSUTENTsunitinib malateCAPSULE;ORAL021938-002Jan 26, 2006RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Cppi CvSUTENTsunitinib malateCAPSULE;ORAL021938-002Jan 26, 2006RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Cppi CvSUTENTsunitinib malateCAPSULE;ORAL021938-004Mar 31, 2009RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Cppi CvSUTENTsunitinib malateCAPSULE;ORAL021938-003Jan 26, 2006RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for CPPI CV drugs

Drugname Dosage Strength Tradename Submissiondate
sunitinib malateCapsules12.5 mg, 25 mg, 37.5 mg and 50 mgSUTENT1/26/2010

Non-Orange Book Patents for Cppi Cv

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,572,924Pyrrole substituted 2-indolinone protein kinase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Cppi Cv Drugs

Country Document Number Estimated Expiration
Slovakia13262002► Subscribe
Portugal1255752► Subscribe
World Intellectual Property Organization (WIPO)0145689► Subscribe
Costa Rica20120007► Subscribe
Peru10832001► Subscribe
Czech Republic20023081► Subscribe
European Patent Office1255752► Subscribe
China1439005► Subscribe
New Zealand519697► Subscribe
Norway2008019► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Cppi Cv Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C003/2010Ireland► SubscribeSPC003/2010: 20100702, EXPIRES: 20240922
2Finland► Subscribe
2010002Lithuania► SubscribePRODUCT NAME: TOCERANIBUM; REGISTRATION NO/DATE: EU/2/09/100/001, 2009 09 23 EU/2/09/100/002, 2009 09 23 EU/2/09/100/003 20090923
2008002,C1255752Lithuania► SubscribePRODUCT NAME: SUNITINIBUM; REGISTRATION NO/DATE: EU/1/06/347/001, EU/1/06/347/002, EU/1/06/347/003 20060719
407Luxembourg► Subscribe91407, EXPIRES: 20210719
1255752/02Switzerland► SubscribePRODUCT NAME: TOCERANIB; REGISTRATION NO/DATE: SWISSMEDIC 60121 09.07.2010
C/GB10/008United Kingdom► SubscribeSUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB10/008 GRANTED TO SUGEN INC. AND PHARMACIA AND UPJOHN COMPANY LLC IN RESPECT OF THE PRODUCT TOCERANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE PHOSPHATE SALT.?, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6380 DATED 31 AUGUST 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 24 SEPTEMBER 2024
2010 00004Denmark► Subscribe
8Finland► Subscribe
2010002,C1255752Lithuania► SubscribePRODUCT NAME: TOCERANIBUM; REGISTRATION NO/DATE: EU/2/09/100/001, 2009 09 23 EU/2/09/100/002, 2009 09 23 EU/2/09/100/003 20090923
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Cerilliant
McKesson
Chubb
Fish and Richardson
AstraZeneca
Accenture
Boehringer Ingelheim
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot